NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
OTTW Ottawa Savings Bancorp Inc
HMC Honda Motor Co Ltd
PAVMZ PAVmed Series Z Equity Warrants Exp 30 Apr 2024 *W EXP 04/30/2024
FFBW Ffbw Inc
CIB Bancolombia SA
TARA Protara Therapeutics Inc
SLAMU Slam Corp
SY So-Young International Inc
BHR Braemar Hotels & Resorts Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Closing Price
$3.64
Day's Change
-0.04 (-1.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.67
Day's Low
3.45
Volume
(Light)
Volume:
23,881

10-day average volume:
71,663
23,881

Deadline Tomorrow Alert: The Schall Law Firm Encourages Investors in Affirm Holdings, Inc. with Losses of $100,000 to Contact the Firm

8:11 am ET April 28, 2022 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - April 28, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Affirm Holdings, Inc. ("Affirm" or "the Company") (NASDAQ: AFRM) for violations of the federal securities laws.

Investors who purchased the Company's shares between February 12, 2021 and February 10, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before April 29, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Affirm tweeted certain metrics from its second quarter 2022 financial report at about 1:15 p.m. on February 10, 2022. The social media post portrayed the Company's quarter as highly successful, including a revenue increase of 77%. The Company then deleted the tweet, and the eventual release of its full second quarter report revealed a loss of $0.57 per share versus analyst expectations of $0.37 per share. The Company's shares then plummeted about 32% from its intraday high. Based on these facts, the Company's public statements were false and materially misleading. When the market learned the truth about Affirm, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/121927

comtex tracking

COMTEX_406382710/2523/2022-04-28T08:11:17

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.